1. Introduction

Anti-dumping law is an important part of international trade regulation. It allows a country to impose additional import duties when a product is exported at a price below its normal value and the imports cause, or threaten to cause, material injury to the domestic industry producing like products.

In the biotechnology and pharmaceutical sectors, anti-dumping law raises complex questions because biological medicines are scientifically complex, expensive to develop, and often difficult to compare directly with competing products.

Biologics include medicines manufactured using living organisms or biological processes, such as:

Monoclonal antibodies used in cancer and autoimmune disease treatment.

Recombinant proteins, including certain insulin products.

Vaccines and therapeutic proteins.

Blood-derived biological products.

Biosimilars, which are highly similar to an already authorised reference biologic, without necessarily being identical in every respect.

Anti-dumping law is distinct from biosimilar approval, patent enforcement, pharmaceutical price regulation, and ordinary customs valuation. A biologic may be safe and lawfully approved for import yet still be subject to an anti-dumping investigation if the relevant legal conditions are met.

The central international framework is the World Trade Organization (WTO) Agreement on Implementation of Article VI of GATT 1994, commonly called the Anti-Dumping Agreement (ADA).

2. Meaning and essential legal elements

Dumping generally occurs when the export price of a product is lower than its normal value, usually the comparable price of the like product in the exporting country's domestic market, subject to the Agreement's rules.

Three principal requirements must be established before an anti-dumping duty can lawfully be imposed.

1. Dumping

The investigating authority establishes a positive dumping margin through a legally valid comparison between export price and normal value.

2. Material injury or qualifying threat

The domestic industry producing the like product must suffer material injury, face a qualifying threat of material injury, or experience material retardation of the establishment of such an industry.

3. Causation

The authority must demonstrate that dumped imports cause the injury and must not attribute injury caused by other known factors to those imports.

These requirements arise principally under Articles 2 and 3 of the Anti-Dumping Agreement. A low import price by itself is insufficient. Nor does a foreign producer's technological advantage or lower production cost automatically establish dumping.

3. Legal framework governing anti-dumping in biologics

A. WTO Anti-Dumping Agreement

The principal provisions are as follows.

World Trade Organization

+1

B. India's anti-dumping framework

For India, the main legislation is Section 9A of the Customs Tariff Act, 1975, read with the Customs Tariff (Identification, Assessment and Collection of Anti-Dumping Duty on Dumped Articles and for Determination of Injury) Rules, 1995.

The Directorate General of Trade Remedies (DGTR), under the Department of Commerce, conducts anti-dumping investigations. The competent central-government authorities perform the relevant functions relating to imposition of duties under the statutory framework.

For a biologic imported into India, the investigation may concern a finished biological medicine, an active biological ingredient, or another specifically defined product, depending on the product scope of the investigation.

A biologic's regulatory approval under India's drug laws does not itself prevent the imposition of a valid anti-dumping duty. Equally, an anti-dumping duty does not itself establish that a medicine is unsafe, ineffective or unlawfully manufactured.

4. Why biologics present special anti-dumping problems

A. Product comparability

Two biologics may target the same disease but differ in molecular structure, formulation, strength, delivery device, indications or manufacturing processes. Investigators must determine whether the products are sufficiently alike under the applicable legal standard and make appropriate adjustments where necessary.

B. Cost of production

Biologics can require specialised facilities, sterile manufacturing, quality-control systems, cold-chain logistics and extensive validation. Authorities must distinguish relevant production costs from research expenses, unusual start-up costs and other accounting items under the applicable rules.

C. Research and development

A low export price may reflect genuine manufacturing efficiency, commercial strategy or market competition. It is not automatically proof of dumping. Investigators must apply the legal normal-value methodology rather than treating high research expenditure as conclusive evidence of an improper price.

D. Public-health consequences

Duties may affect the affordability and availability of biologics, including biosimilars used in cancer care, diabetes and autoimmune diseases. These consequences matter to policy design, although they do not eliminate the legal requirements for proving dumping, injury and causation.

5. Determining dumping: normal value versus export price

Article 2 of the WTO Anti-Dumping Agreement provides the starting point for the calculation.

Anti-Dumping Agreement

+1

A. Normal value

Normal value is ordinarily based on comparable domestic-market sales of the like product in the exporting country, in the ordinary course of trade.

Where qualifying domestic sales are unavailable or do not permit a proper comparison, the authority may use an appropriate third-country export price or a constructed normal value based on production costs plus reasonable administrative, selling and general expenses and profit, as permitted by the Agreement.

In biologics cases, the authority may need to examine:

Whether the reference product and exported product are comparable.

Differences in dosage, packaging, commercial level and delivery systems.

Whether domestic sales are representative and made in the ordinary course of trade.

Whether manufacturing costs and cost allocations are supported by reliable records.

Whether any adjustments are justified by evidence.

B. Export price

Export price is generally the price at which the product is exported to the importing country. Where the price is unreliable because of an association or compensatory arrangement between the exporter and importer, the authority may construct an export price under the applicable rules.

For example, a biologic sold by a manufacturer to an affiliated distributor may pass through several commercial stages before reaching hospitals. The authority must carefully identify the relevant export price and make legally justified adjustments rather than simply comparing unrelated invoice prices.

C. Illustrative calculation

Suppose an imported biologic has the following hypothetical values per standardised treatment unit:

Normal value

₹12,000

Export price

₹9,000

Illustrative price difference

₹3,000

Illustrative dumping margin

33.33%

Calculation: (₹12,000 − ₹9,000) ÷ ₹9,000 × 100 = 33.33%. The export price is the denominator in this illustration. The figures are hypothetical, and this is not a finding that dumping has occurred.

The actual investigation must follow the applicable rules on fair comparison, adjustments and margin calculation. A dumping margin is not automatically the same as the final anti-dumping duty rate.

6. Injury, causation and the domestic biologics industry

Under Article 3, an authority must objectively assess evidence of material injury. Relevant factors can include:

Import volume and its development over time.

Undercutting of domestic prices.

Price depression or suppression.

Domestic production, sales and market share.

Profitability, capacity utilisation, employment and investment.

Other relevant economic factors affecting the industry.

In a biologics investigation, a domestic producer may argue that low-priced imported biosimilars have forced it to reduce prices or have prevented it from recovering reasonable commercial returns.

However, the authority must distinguish the effects of dumped imports from other known causes, such as:

Expiry of patents or regulatory exclusivities.

Entry of additional biosimilar competitors.

Changes in hospital procurement and public tenders.

Domestic manufacturing inefficiency or production interruptions.

Falling input costs or changes in demand.

Regulatory delays, product recalls or shortages unrelated to imports.

A finding that domestic sales or profits declined is not, by itself, sufficient. The authority must establish the legally required causal link to dumped imports.

World Trade Organization

+1

7. Important case laws relevant to anti-dumping in biologics

There are relatively few reported anti-dumping decisions specifically concerning biologic medicines. The following WTO disputes therefore provide important legal principles that can be applied by analogy to biologics investigations. They are not judgments holding that a particular biologic was dumped.

Case 1: European Communities – Bed Linen (DS141)

WTO Appellate Body Report, adopted 12 March 2001

Facts: India challenged anti-dumping duties imposed by the European Communities on cotton-type bed linen exported from India.

Legal issue: Whether the method used to calculate dumping margins, including the practice known as zeroing, complied with WTO anti-dumping rules.

Decision: The Appellate Body upheld the finding that the zeroing methodology used in the investigation was inconsistent with Article 2.4.2 of the Anti-Dumping Agreement. The dispute also examined the calculation of normal value and aspects of the injury determination.

DS141

+1

Application to biologics: An authority investigating imported monoclonal antibodies or biosimilars must calculate dumping margins using a legally permissible methodology. It cannot manipulate the comparison of product transactions to inflate the margin.

The case is particularly relevant where products have different strengths, packaging configurations or transaction prices and the authority must make a fair comparison.

Case 2: United States – Hot-Rolled Steel from Japan (DS184)

WTO Appellate Body Report, adopted 23 August 2001

Facts: Japan challenged US anti-dumping measures on hot-rolled steel products, including aspects of normal-value calculations and the treatment of information submitted by exporters.

Legal issue: Whether the investigating authority properly handled exporter information and established dumping and injury in accordance with the Agreement.

Decision: The WTO dispute settlement process found inconsistencies involving the use of facts available under Article 6.8 and Annex II, and the treatment of certain affiliated-party sales. The Appellate Body also reversed the panel's finding concerning the injury and causation analysis, finding the causal relationship determination insufficiently supported under the Agreement.

DS184

+1

Application to biologics: A foreign biologics manufacturer may possess extensive batch records, production-cost data, transfer-pricing records and confidential commercial information. An authority must apply the rules on facts available appropriately and provide a legally adequate basis for its findings.

A company should not automatically receive an adverse dumping margin simply because some records were submitted late. The authority must assess the circumstances under the applicable rules.

Case 3: United States – Anti-Dumping and Countervailing Measures on Steel Plate from India (DS206)

WTO dispute concerning US measures on steel plate from India

Facts: India challenged US determinations concerning steel plate imports, including the handling of information in anti-dumping and countervailing duty investigations.

Legal significance: The dispute illustrates the importance of complying with WTO disciplines governing investigative evidence and the determination of injury.

DS206

+1

Application to biologics: If a biologics exporter submits reliable manufacturing-cost information, clinical-product specifications or transaction records, the investigating authority must evaluate that evidence under the relevant legal framework. The authority's conclusions must rest on the evidence and applicable rules rather than unsupported assumptions.

Case 4: European Communities – Bed Linen, Article 21.5 compliance proceedings

WTO compliance proceedings, 2002–2003

Facts: After the original dispute, India challenged aspects of the European Communities' implementation of the WTO recommendations.

Legal significance: The compliance proceedings examined the revised measures and the treatment of injury and other issues. The resulting reports show that a country must bring a measure into conformity with WTO obligations rather than merely repeat an earlier determination in a new form.

World Trade Organization

+1

Application to biologics: If a biologics duty is successfully challenged, the investigating authority must correct the legal defects identified in the proceedings. Reassessment should address the specific deficiencies in the dumping calculation, injury analysis or procedure.

Case 5: India's domestic judicial review of anti-dumping determinations

In India, anti-dumping disputes may reach the constitutional courts through judicial review and may also involve statutory appellate or tribunal procedures applicable to the particular dispute.

A useful starting point for research is Reliance Industries Ltd. v. Designated Authority, (2006) 10 SCC 368. It is associated with the Indian judicial treatment of anti-dumping determinations and review issues. The precise holding should be checked against the full judgment before relying on it for a particular proposition concerning biologics.

For a biologics-specific case, counsel should additionally examine DGTR final findings, relevant customs notifications, and subsequent judicial or appellate orders concerning the precise product and country of origin. The WTO cases above are general anti-dumping authorities, not substitutes for product-specific Indian findings.

8. Anti-dumping versus other legal controls in biologics

The distinction between different legal mechanisms is essential.

These mechanisms have different legal tests. In particular, an anti-dumping duty is not proof of a patent violation or a pharmaceutical safety defect.

9. Procedure for an anti-dumping investigation involving biologics in India

Application by domestic industry. A qualifying domestic producer or industry association submits evidence of dumping, injury and causation.

Definition of the product. The authority specifies the product under investigation, including relevant formulations, product forms, origins and exclusions where justified.

Initiation and questionnaires. DGTR examines the application and, where the legal requirements are met, initiates an investigation and seeks information from exporters, importers and domestic producers.

Verification and comparison. The authority examines transaction prices, cost records, normal value, product comparability and appropriate adjustments.

Injury assessment. It assesses import volumes, price effects and the domestic industry's condition, while separating the effects of other known causes.

Findings and opportunity to respond. Interested parties must receive the procedural opportunities required by the applicable rules to present evidence and address the case against them.

Final findings and duty decision. The authority issues its findings, after which the competent government authority acts under the applicable statutory framework.

Review and challenge. Interested parties may pursue the available statutory remedies or judicial review, and duties may be reviewed under the applicable rules.

The WTO Agreement's Article 5 governs initiation; Article 6 governs evidence and procedural rights; and Article 11 addresses the duration and review of measures.

World Trade Organization

+1

10. Legal defences available to biologics exporters

An exporter or importer facing an anti-dumping investigation may consider several evidence-based arguments.

First, challenge the normal value. The exporter may demonstrate that the authority has used an inappropriate comparison market, improperly constructed production costs or failed to make necessary adjustments.

Second, challenge product comparability. If the authority compares products with materially different characteristics, the exporter may argue that the comparison is not fair. Differences must be evaluated according to the legal definition of the like product and the applicable adjustment rules.

Third, challenge the injury analysis. The exporter may show that domestic producers' difficulties resulted from regulatory delays, supply interruptions, inefficiency, changes in demand or other factors rather than dumped imports.

Fourth, challenge the evidence and procedure. The exporter may contest unsupported adverse assumptions, inadequate disclosure of essential facts, or a failure to consider relevant submissions.

Fifth, distinguish dumping from legitimate commercial pricing. Lower production costs, technological efficiency and competitive pricing can be relevant evidence. They do not, however, automatically defeat a properly calculated dumping margin.

Sixth, consider the public-health context. Where the imported product is a critical medicine, the parties may raise affordability, availability and supply-security concerns in the appropriate policy or legal forum. Such concerns should not be confused with the evidentiary requirements for establishing dumping.

11. Policy concerns: domestic industry protection and access to medicines

Anti-dumping rules seek to address injurious dumping while preserving a rules-based trading system. In biologics, their application can affect both industrial development and access to treatment.

Excessive or poorly supported duties can increase import costs and reduce competition. Conversely, injurious dumping, where legally established, can damage domestic manufacturing capacity and discourage investment.

Governments should therefore distinguish between legitimate price competition and conduct meeting the legal test for anti-dumping action. The analysis should also consider whether domestic production capacity is genuinely substitutable for imported biologics, particularly where manufacturing requires specialised facilities or the medicine has limited alternative suppliers.

Article 15 of the Anti-Dumping Agreement recognises the special situation of developing-country Members and calls for exploration of constructive remedies before imposing duties where those remedies would affect their essential interests. This is not an automatic exemption from anti-dumping duties, but it is a relevant consideration in the WTO framework.

World Trade Organization

+1

12. Conclusion

Anti-dumping in biologics trade lies at the intersection of international trade law, pharmaceutical manufacturing, biotechnology regulation and public health.

The essential legal principle is that a low-priced imported biologic cannot lawfully be subjected to an anti-dumping duty merely because it competes with domestic producers. The investigating authority must establish dumping through a lawful price comparison, demonstrate material injury or another qualifying form of injury, and establish causation in accordance with the applicable rules.

The WTO decisions in EC – Bed Linen, US – Hot-Rolled Steel and US – Steel Plate from India provide useful guidance on dumping-margin calculations, evidentiary standards and injury analysis. Their principles can inform biologics investigations, although each dispute must be applied within its own legal and factual limits.

For India, Section 9A of the Customs Tariff Act, 1975, the 1995 Anti-Dumping Rules, DGTR findings and applicable judicial decisions form the core domestic framework. A complete case-specific opinion should identify the exact biologic, exporting country, product scope, relevant investigation and applicable duty notification.